OT Staff Reports

Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.

Steffen E. Künzel, MD, discusses the key points of his research presentation regarding low vulnerability of the posterior eye segment to SARS-CoV-2 infection.

Uwe Oberheide, MD, discusses the key findings of his virtual ARVO 2021 presentation on modeling of IOLs for patients with AMD by ray-tracing.

Seth Miller, clinical operations manager at Ora Inc., discusses the relationship between the symptoms of dry eye and aging, based on his ARVO 2021 presentation.

Jeffrey Gemi, MD, Ora Inc., speaks on the highlights from his presentation comparing Schirmer's test with other clinical outcomes in dry eye.

George Waring IV, MD serves as guest host for ‘History and Evolution of Contemporary Refractive Surgery’

SemaThera Inc. has announced a research collaboration and licensing agreement with Roche to develop a new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases.

Peter J. Polack, MD, FACS, and Zora Harrison, COO at Ocala Eye, discuss their adaptive approach to the pandemic in implementing health/social distancing guidelines and technology for patients and staff.

Peter J. Polack, MD, FACS, of Ocala Eye, discusses how proper patient education and nutrition have been key to managing an increase in dry eye patients during the pandemic.

Peter J. Polack, MD, FACS, and Zora Harrison, COO at Ocala Eye, share the protocols and technology their practice implemented throughout the pandemic that has enabled them to safely and efficiently treat their patients.

Rachel Curtis, MD, a fourth-year resident at Queen's University, Kingston, Ontario, Canada, discusses the highlights from a study comparing a smartphone-compatible device versus traditional direct ophthalmoscopy in teaching medical students how to complete an optic nerve examination.

To mark the 20th anniversary of its TECNIS IOLs, Johnson & Johnson Vision is launching the “See More” campaign to educate patients and physicians on what is possible with cataract surgery.

Aleksandra Rachitskaya, MD, speaks on the current gaps in AMD treatment as well as ongoing retinal advancements to help address unmeet needs of patients.

Kuldev Singh, MD, MPH, professor/director of the Glaucoma Service Stanford Medical Center, shares the highlights from his discussion on surgical procedure decision-making in the era of MIGS.

Shan C. Lin, MD, co-research director, Glaucoma Center of San Francisco, speaks on the highlights from his presentation on the latest in the three forms of cyclophotocoagulation commonly used by clinicians.

The session duration is 4 hours per week over the course of about 6 months, according to Jorge L. Alió, MD, PhD, FEBO, director of the course.

Calling all physicians — take this survey and let us know your thoughts on the COVID-19 vaccine.

J. Michael Jumper, MD, a retinal specialist at West Coast Retina (San Francisco, CA), discusses the highlights of his Glaucoma 360 presentation analyzing the impact and lasting effects of intraocular injections and retinal diseases in creating glaucoma as well as the evolving collaboration between retinal and glaucoma specialists.

L. Jay Katz, MD, of the Wills Eye Hospital, Philadelphia, PA, discusses the highlights of his Glaucoma 360 presentation on secondary glaucoma due to intravitreal steroids, and what ophthalmologists can do to minimize the risk of severe visual impairment in patients.

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.

Ian C. Han, MD, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.

Oluwatosin U. Smith, MD, Glaucoma Associates of Texas, provides an update on optimization and surgical modifications of newer glaucoma surgeries.

Joseph F. Panarelli, MD, associate professor of ophthalmology, NYU Langone Medical Center, shares some clinical pearls for managing masquerade syndromes and determining when it is not glaucoma.

Investigators at the Wilmer Eye Institute at the Johns Hopkins University School of Medicine conducting experiments in mouse tissues and human cells found that they may be able improve the success rate for regrowing nerve cells damaged by blinding diseases.

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.

John H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his story.